The journey of Augmentin: key milestones

Augmentin™

- **1928**: Alexander Fleming identified Penicillin
- **1957**: Beecham Research Laboratories (BRL) identified 6-APA; 6-aminopenicillanic acid to be used later for development of semi-synthetic penicillins
- **1960**: Methicillin
- **1961**: Ampicillin
- **1962**: Cloxacillin
- **1972**: Amoxicillin

**1960-72**: Introduction of tablet formulations of Augmentin in UK

**1981**: Introduction of Alexander Project, an international multicentre surveillance study by SmithKline Beecham

**1992**: Development of high dose pharmacokinetically enhanced Augmentin XR
- Development of Augmentin ES based on PK/PD considerations

**2001 onwards**: Survey of Antibiotic Resistance (SOAR) established to provide information on local resistance patterns

**2002 onwards**: Launch of 7:1 twice daily formulations of Augmentin for adults and pediatric patients

**Mid 1990’s**: Even after 3 decades of its launch, the rationale for using Augmentin remains unchanged

**Launch of 7:1 twice daily formulations of Augmentin for adults and pediatric patients**

**Introduction of Alexander Project an international multicentre surveillance study by SmithKline Beecham**

**Survey of Antibiotic Resistance (SOAR) established to provide information on local resistance patterns**

**Development of high dose pharmacokinetically enhanced Augmentin XR**

**Introduction of tablet formulations of Augmentin in UK**

**BRL develops clavulanic acid from Streptococcus clavuligerus**

**1928**: Development of high dose pharmacokinetically enhanced Augmentin XR

**1957**: Development of Augmentin ES based on PK/PD considerations

**1981**: Survey of Antibiotic Resistance (SOAR) established to provide information on local resistance patterns

**1992**: Launch of 7:1 twice daily formulations of Augmentin for adults and pediatric patients

**2001 onwards**: Even after 3 decades of its launch, the rationale for using Augmentin remains unchanged

**References:**
Main Augmentin Safety Statement:

- Contraindicated in patients with known hypersensitivity to beta-lactam antibiotics (penicillins and cephalosporins)
- Gastrointestinal disturbances are common
- Prolonged use may result in overgrowth of non-susceptible organisms
- Contraindicated in patients with history of jaundice/hepatic impairment due to amoxicilin/clavulinic acid treatment.